SCHEMBL19998608

SCHEMBL19998608

CN1CCCN(Cc2c(F)cccc2Cl)CC1

nearest known ligand 0.89

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A13 Q16696 1/20 0.61
CHKA P35790 5/20 0.56
ALDH1A1 P00352 3/20 0.56
TDP1 Q9NUW8 3/20 0.56
ALOX15 P16050 1/20 0.56
LMNA P02545 2/20 0.56
PKM P14618 1/20 0.56
GAA P10253 2/20 0.55
HSD11B1 P28845 1/20 0.54
CA2 P00918 1/20 0.52
NCF1 P14598 1/20 0.52
PRMT6 Q96LA8 1/20 0.52
KDM4E B2RXH2 3/20 0.51
POLB P06746 2/20 0.51
TSHR P16473 2/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
CACNA1G O43497 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4109734 0.83 CYP2A13 (0.62) CYP2A13CHKAALDH1A1TDP1ALOX15
SCHEMBL18389944 0.83 ALDH1A1 (0.62) CYP2A13CHKAALDH1A1TDP1ALOX15
SCHEMBL14608742 0.82 CYP2A13 (0.64) CYP2A13ALDH1A1TDP1ALOX15LMNA
SCHEMBL14459986 0.80 CYP2A13 (0.61) CYP2A13ALDH1A1TDP1ALOX15LMNA
SCHEMBL12732277 0.79 CYP2A13 (0.59) CYP2A13ALDH1A1TDP1ALOX15LMNA
SCHEMBL656160 0.78 CYP2A13 (0.62) CYP2A13ALDH1A1TDP1ALOX15LMNA
SCHEMBL18753878 0.77 ALDH1A1 (0.51) CYP2A13CHKAALDH1A1TDP1ALOX15
SCHEMBL2010728 0.77 CYP2A13 (0.61) CYP2A13ALDH1A1TDP1ALOX15LMNA
SCHEMBL12709637 0.77 CYP2A13 (0.57) CYP2A13ALDH1A1TDP1ALOX15LMNA
SCHEMBL4107051 0.76 CYP2A13 (1.00) CYP2A13ALDH1A1TDP1ALOX15LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3943490-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS Mission Therapeutics Limited (GB) 2022-01-26 EP disclosed
US-11066365-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors MISSION THERAPEUTICS LIMITED (GB) 2021-07-20 US disclosed
EP-3277677-B9 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LTD (GB) 2021-07-14 EP disclosed
US-11053198-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors MISSION THERAPEUTICS LIMITED (GB) 2021-07-06 US disclosed
EP-3842427-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS Mission Therapeutics Limited (GB) 2021-06-30 EP disclosed
EP-3277677-B1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LTD (GB) 2021-02-24 EP disclosed
US-10689345-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors MISSION THERAPEUTICS LIMITED (GB) 2020-06-23 US disclosed
US-20200181086-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2020-06-11 US disclosed
US-20190322624-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2019-10-24 US disclosed
US-20190284138-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2019-09-19 US disclosed
US-20190270708-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2019-09-05 US disclosed
US-10343992-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors Missions Therapeutics Limited (GB) 2019-07-09 US disclosed
US-20180086708-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2018-03-29 US disclosed
US-20180086708-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2018-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11066365-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP20, USP10 CYP2A13 3249/4885CHKA 2700/4885ALDH1A1 1172/4885
US-10343992-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP20, USP10 CYP2A13 3702/4885CHKA 2799/4885ALDH1A1 1264/4885
US-11053198-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP20, USP10 CYP2A13 3702/4885CHKA 2799/4885ALDH1A1 1264/4885
US-20200181086-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS USP30, USP20, USP10 CYP2A13 3850/4885CHKA 2661/4885ALDH1A1 1220/4885
US-20190284138-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS USP30, USP20, USP10 CYP2A13 3249/4885CHKA 2700/4885ALDH1A1 1172/4885
US-20180086708-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS USP30, USP20, USP10 CYP2A13 3702/4885CHKA 2799/4885ALDH1A1 1264/4885
US-20190322624-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS USP30, USP20, USP10 CYP2A13 3702/4885CHKA 2799/4885ALDH1A1 1264/4885
US-10689345-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP20, USP10 CYP2A13 3702/4885CHKA 2799/4885ALDH1A1 1264/4885
US-20190270708-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS USP30, USP20, USP10 CYP2A13 3702/4885CHKA 2799/4885ALDH1A1 1264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.